Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients
December 08, 2022 07:00 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Dec. 08, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and...
Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million
December 07, 2022 08:35 ET
|
Palisade Bio, Inc.
Proceeds extend cash runway to fund operations into early 2024 Carlsbad, CA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company...
Palisade Bio Regains Compliance with Nasdaq Listing Requirements
December 01, 2022 14:44 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Palisade Bio is Granted Fast Track Designation from the U.S. Food and Drug Administration for LB1148 for Accelerated Return of Bowel Function following GI Surgery
November 22, 2022 08:35 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for avoidance of acute and chronic...
Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer
November 18, 2022 08:05 ET
|
Palisade Bio, Inc.
Established academic and corporate executive with proven track record leading large, multinational organizations across the pharmaceutical and medical device industries Well-versed with LB1148 -...
Palisade Bio Releases In-Depth Explanation of Scientific Approach of Lead Product Candidate LB1148 Through Animated Video
November 17, 2022 08:30 ET
|
Palisade Bio, Inc.
Video illustrates the potential of LB1148 to reduce the formation of adhesions in gastrointestinal (GI) tissues and accelerate the time to the return of normal GI function Carlsbad, CA, Nov. 17,...
Palisade Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
November 14, 2022 08:45 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc., (Nasdaq: PALI) a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Bioxytran Scientific Advisor Releases New Book on Brain Metabolism
October 25, 2022 07:00 ET
|
BIOXYTRAN, INC.
The book contains all aspects of brain energy metabolism and other physiological functions related to Cortical Spreading Depression which is the essence of how the brain consumes oxygen. BOSTON,...
BioRestorative Therapies to Present at the Dawson James Securities 7th Annual Small Cap Growth Conference
September 28, 2022 07:00 ET
|
BioRestorative Therapies, Inc
MELVILLE, NY., Sept. 28, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
Processa Pharmaceuticals Provides Update on Enrollment Across all Clinical Programs
September 15, 2022 08:30 ET
|
Processa Pharmaceuticals, Inc.
PCS12852 for Gastroparesis concluded enrollment a month ahead of schedule. Statistics on gastric emptying, safety and GEBT data will be available by the end of October and full topline data is...